FULC

3.32

1.84% 0.06

Handel nachbörslich: 3.31 -0.010 -0.30%

Fulcrum Therapeutics Inc (FULC)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$3.26

Offen:

$3.28

24-Stunden-Volumen:

985.33K

Relative Volume:

0.61

Marktkapitalisierung:

$207.17M

Einnahmen:

$2.81M

Nettoeinkommen (Verlust:

$-97.34M

KGV:

-1.8444

EPS:

-1.8

Netto-Cashflow:

$-91.47M

1W Leistung:

+2.47%

1M Leistung:

-13.09%

6M Leistung:

-57.16%

1J Leistung:

-14.65%

1-Tages-Spanne:

$3.21

$3.345

1-Wochen-Bereich:

$3.13

$3.38

52-Wochen-Spanne:

$2.865

$13.70

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Firmenname

Fulcrum Therapeutics Inc

Sektor

Healthcare (1182)

Branche

Biotechnology (671)

Telefon

617-651-8851

Adresse

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Mitarbeiter

Twitter

@fulcrumtx

Nächster Verdiensttermin

2024-11-05

Neueste SEC-Einreichungen

FULC's Discussions on Twitter

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-05-04	Herabstufung	Goldman	Buy → Neutral
2023-03-10	Herabstufung	Credit Suisse	Outperform → Neutral
2023-03-10	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-03-09	Herabstufung	Stifel	Buy → Hold
2023-02-28	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2023-02-24	Herabstufung	BofA Securities	Neutral → Underperform
2022-11-15	Eingeleitet	Goldman	Buy
2022-03-08	Eingeleitet	Oppenheimer	Outperform
2022-03-03	Hochstufung	BofA Securities	Underperform → Neutral
2021-08-11	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2021-04-26	Fortgesetzt	Credit Suisse	Outperform
2021-03-22	Eingeleitet	Credit Suisse	Outperform
2021-03-02	Eingeleitet	Stifel	Buy
2020-10-16	Eingeleitet	Piper Sandler	Overweight
2020-08-12	Herabstufung	BofA Securities	Neutral → Underperform
2020-08-12	Bestätigt	H.C. Wainwright	Buy
2020-08-12	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2020-06-19	Herabstufung	BofA/Merrill	Buy → Neutral
2020-06-17	Eingeleitet	BTIG Research	Buy
2019-10-03	Eingeleitet	H.C. Wainwright	Buy
2019-08-12	Eingeleitet	BofA/Merrill	Buy

Alle ansehen

Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten

02:29 AM

Vanguard Group Inc's Strategic Acquisition in Fulcrum Therapeuti - GuruFocus.com

02:29 AM

Nov 02, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Assenagon Asset Management S.A. - MarketBeat

Nov 02, 2024

Oct 31, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Update - MarketBeat

Oct 31, 2024

Oct 26, 2024

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of "Hold" from Brokerages - MarketBeat

Oct 26, 2024

Oct 21, 2024

We're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To Grow - Yahoo Finance

Oct 21, 2024

Oct 14, 2024

Ratios in Focus: Analyzing Fulcrum Therapeutics Inc (FULC)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 14, 2024

Oct 11, 2024

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 11, 2024

Zevra Stock Surges Close to 70% in 3 Months: Here's Why - MSN

Oct 11, 2024

Oct 10, 2024

The FULC Stock Puzzle: Unraveling Fulcrum Therapeutics Inc’s Fluctuating Performance - The InvestChronicle

Oct 10, 2024

Are Smart Investors Making the Right Decision? Fulcrum Therapeutics Inc (FULC) - SETE News

Oct 10, 2024

Further weakness as Fulcrum Therapeutics (NASDAQ:FULC) drops 12% this week, taking three-year losses to 88% - Simply Wall St

Oct 10, 2024

Oct 09, 2024